Cargando…

Acute myocarditis after a third dose of the BNT162b2 COVID-19 vaccine

Detalles Bibliográficos
Autores principales:	Fosch, Xavier, Serra, Julia, Torres, Pedro L., Preda, Luminita, González, Rosa, Mojer, Francisca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903822/ https://www.ncbi.nlm.nih.gov/pubmed/35277352 http://dx.doi.org/10.1016/j.rec.2022.01.009

Ejemplares similares

Miocarditis aguda tras la tercera dosis de la vacuna BNT162b2 contra la COVID-19
por: Fosch, Xavier, et al.
Publicado: (2022)

Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer
por: Di Noia, V., et al.
Publicado: (2022)

CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?
por: Di Noia, Vincenzo, et al.
Publicado: (2022)

Humoral and cellular responses to the third COVID-19 BNT162b2 vaccine dose in research institute workers in Japan
por: Nishikimi, Akihiko, et al.
Publicado: (2023)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Mevorach, Dror, et al.
Publicado: (2022)

Acute myocarditis following administration of BNT162b2 vaccine
por: Habib, Mhd Baraa, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Witberg, Guy, et al.
Publicado: (2022)

Acute Myocarditis Following the Administration of the Second BNT162b2 COVID-19 Vaccine Dose
por: Miqdad, Mohammed A, et al.
Publicado: (2021)

Acute myocarditis after receiving first dose of BNT162b2 mRNA vaccine
por: Wu, Bryan, et al.
Publicado: (2022)

Myocarditis after BNT162b2 vaccination in a healthy male
por: Watkins, Kevin, et al.
Publicado: (2021)

Humoral and cellular responses to vaccination with homologous CoronaVac or ChAdOx1 and heterologous third dose with BNT162b2
por: Hayashi, Jackelinne Y., et al.
Publicado: (2022)

Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer
por: Debie, Yana, et al.
Publicado: (2022)

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
por: Moreira, Edson D., et al.
Publicado: (2022)

Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19
por: Bautista García, Javier, et al.
Publicado: (2021)

Acute myocarditis after administration of BNT162b2 vaccine against COVID-19
por: Cueva-Recalde, Juan F., et al.
Publicado: (2023)

Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines
por: Naveed, Zaeema, et al.
Publicado: (2022)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience
por: Peled, Yael, et al.
Publicado: (2022)

Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population()
por: Kawasuji, Hitoshi, et al.
Publicado: (2022)

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
por: Patalon, Tal, et al.
Publicado: (2022)

Reply to Mungmunpuntipantip and Wiwanitkit: CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mok, Chris Ka Pun, et al.
Publicado: (2022)

Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients
por: Bertrand, Dominique, et al.
Publicado: (2021)

Amplitudes and kinetic of antibodies after second and third doses of BNT162b2 vaccine in nonagenarians and centenarians with and without prior SARS-CoV-2 infection
por: Tuaillon, Edouard, et al.
Publicado: (2022)

Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response
por: Costard-Jäckle, Angelika, et al.
Publicado: (2022)

Saliva and Plasma Neutralizing Activity Induced by the Administration of a Third bnt162b2 Vaccine Dose
por: Garziano, Micaela, et al.
Publicado: (2022)

Safety and Efficacy of a Third Dose of the BNT162b2 Vaccine in Liver-Transplanted and Healthy Adolescents
por: Sintusek, Palittiya, et al.
Publicado: (2023)

Giant cell myocarditis after first dose of BNT162b2 – a case report
por: Hirsch, Valentin G., et al.
Publicado: (2022)

A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients
por: Natori, Yoichiro, et al.
Publicado: (2023)

Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru
por: Vargas-Herrera, Natalia, et al.
Publicado: (2022)

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
por: Renia, Laurent, et al.
Publicado: (2022)

Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population
por: Malissen, Nausicaa, et al.
Publicado: (2021)

Third-Dose BNT162b2 Vaccination Elicits Markedly High-Level SARS-CoV-2–Neutralizing Antibodies in Vaccinees Who Responded Poorly to a Second Dose in Japan
por: Amano, Masayuki, et al.
Publicado: (2022)

Unilateral Pleural Effusion after Third Dose of BNT162b2 mRNA Vaccination: Case Report
por: Athanasiou, Nikolaos K., et al.
Publicado: (2023)

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
por: Mevorach, Dror, et al.
Publicado: (2021)

Myocarditis Following COVID-19 BNT162b2 Vaccination Among Adolescents in Hong Kong
por: Li, Xue, et al.
Publicado: (2022)

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
por: Redjoul, Rabah, et al.
Publicado: (2021)

Favorable Humoral Response to Third Dose of BNT162b2 in Patients Undergoing Hemodialysis
por: Kitamura, Mineaki, et al.
Publicado: (2022)

Boosting capacity of a fourth dose BNT162b2 in cancer patients
por: Debie, Yana, et al.
Publicado: (2023)

Waning antibody response and cellular immunity 6 months after third dose SARS-Cov-2 mRNA BNT162b2 vaccine in kidney transplant recipients
por: Bertrand, Dominique, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qlbv83vm38tdtbvlidptdrm4qa